New Pooled Analysis Published in The Lancet Demonstrated Reduced Risk of Combined CV Death or Worsening Heart Failure with Semaglutide
New pooled analysis in The Lancet shows semaglutide reduces risk of combined CV death or worsening heart failure by 31%, with a 41% lower risk of worsening HF. Semaglutide not approved for heart failure outcomes in the US. Analysis included 3,743 HFpEF patients from four trials.
Highlighted Terms
Related News
New pooled analysis in The Lancet shows semaglutide reduces risk of combined CV death or worsening heart failure by 31%, with a 41% lower risk of worsening HF. Semaglutide not significant for CV death risk. Study involved 3,743 HFpEF patients from SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM trials. Semaglutide not approved in the US for heart failure outcomes.
New pooled analysis in The Lancet shows semaglutide reduces risk of combined CV death or worsening heart failure by 31%, with a 41% lower risk of worsening HF. Semaglutide not approved for heart failure outcomes in the US. Analysis included 3,743 HFpEF patients from four trials.